Skip to main content
Erschienen in: Virchows Archiv 1/2018

25.05.2018 | Original Article

Primary adrenal diffuse large B cell lymphoma: a clinicopathological and molecular study from China

verfasst von: Jing Zhang, Jian Sun, Jun Feng, Yufeng Luo, Qing Ling, Shafei Wu, Xuan Zeng, Zhiyong Liang

Erschienen in: Virchows Archiv | Ausgabe 1/2018

Einloggen, um Zugang zu erhalten

Abstract

Primary adrenal lymphoma is a rare entity that, in most cases, is derived from B cells. The most commonly seen primary adrenal lymphoma is diffuse large B cell lymphoma (DLBCL). To better understand the clinicopathological and molecular features of these tumors, we studied 14 Chinese patients with DLBCL who initially presented with an adrenal tumor. The clinicopathological features of the 14 primary adrenal DLBCL cases were retrospectively reviewed using immunohistochemistry, immunoglobulin gene rearrangement analysis, evaluation of Epstein-Barr virus status, and fluorescence in situ hybridization. Patient age ranged from 43 to 69 years, with a mean age of 58 years. The patients most commonly presented with abdominal pain and adrenal mass. Ten patients exhibited bilateral adrenal masses, and four had unilateral adrenal masses (three left, one right). Thirteen of 14 DLBCLs were DLBCL not otherwise specified, and one was an intravascular large B cell lymphoma. According to the algorithm of Hans et al. (Blood 103:275–282, 2004), 13 and 1 cases were classified as the non-germinal center B-cell-like subtype and the germinal center B-cell-like subtype, respectively. The Ki-67 index ranged from 35 to 80%. Epstein-Barr virus-encoded RNA was detected by in situ hybridization in 6 of the 12 available cases. Two patients showed BCL-6 rearrangements. The follow-up period ranged from 1 to 87 months. During the follow-up period, four patients died of the disease, five were alive with the disease, four were alive without disease, and one was lost during the follow-up period. In summary, most primary adrenal lymphomas are non-germinal-center B-cell-like subtype DLBCLs, which have high proliferative activity and a poor prognosis.
Literatur
1.
Zurück zum Zitat Paling MR, Williamson BR (1983) Adrenal involvement in non-Hodgkin lymphoma. AJR Am J Roentgenol 141:303–305CrossRefPubMed Paling MR, Williamson BR (1983) Adrenal involvement in non-Hodgkin lymphoma. AJR Am J Roentgenol 141:303–305CrossRefPubMed
3.
Zurück zum Zitat Mozos A, Ye H, Chuang WY, Chu JS, Huang WT, Chen HK, Hsu YH, Bacon CM, Du MQ, Campo E, Chuang SS (2009) Most primary adrenal lymphomas are diffuse large B-cell lymphomas with non-germinal center B-cell phenotype, BCL6 gene rearrangement and poor prognosis. Mod Pathol 22:1210–1217CrossRefPubMed Mozos A, Ye H, Chuang WY, Chu JS, Huang WT, Chen HK, Hsu YH, Bacon CM, Du MQ, Campo E, Chuang SS (2009) Most primary adrenal lymphomas are diffuse large B-cell lymphomas with non-germinal center B-cell phenotype, BCL6 gene rearrangement and poor prognosis. Mod Pathol 22:1210–1217CrossRefPubMed
4.
Zurück zum Zitat Rashidi A, Fisher SI (2013) Primary adrenal lymphoma: a systematic review. Ann Hematol 92:1583–1593CrossRefPubMed Rashidi A, Fisher SI (2013) Primary adrenal lymphoma: a systematic review. Ann Hematol 92:1583–1593CrossRefPubMed
5.
Zurück zum Zitat Kim YR, Kim JS, Min YH, HyunYoon D, Shin HJ, Mun YC, Park Y, Do Y, Jeong S, Park J, Oh S, Lee S, Park E, Jang JS, Lee WS, Lee HW, Eom HS, Ahn JS, Jeong JH, Baek S, Kim S, Kim W, Suh C (2012) Prognostic factors in primary diffuse large B-cell lymphoma of adrenal gland treated with rituximab-CHOP chemotherapy from the consortium for improving survival of lymphoma (CISL). J Hematol Oncol 5:49CrossRefPubMedPubMedCentral Kim YR, Kim JS, Min YH, HyunYoon D, Shin HJ, Mun YC, Park Y, Do Y, Jeong S, Park J, Oh S, Lee S, Park E, Jang JS, Lee WS, Lee HW, Eom HS, Ahn JS, Jeong JH, Baek S, Kim S, Kim W, Suh C (2012) Prognostic factors in primary diffuse large B-cell lymphoma of adrenal gland treated with rituximab-CHOP chemotherapy from the consortium for improving survival of lymphoma (CISL). J Hematol Oncol 5:49CrossRefPubMedPubMedCentral
6.
Zurück zum Zitat Ozimek A, Diebold J, Linke R, Heyn J, Hallfeldt KK, Mussack T (2008) Bilateral primary adrenal non-Hodgkin’s lymphoma—a case report and review of the literature. Eur J Med Res 13:221–228PubMed Ozimek A, Diebold J, Linke R, Heyn J, Hallfeldt KK, Mussack T (2008) Bilateral primary adrenal non-Hodgkin’s lymphoma—a case report and review of the literature. Eur J Med Res 13:221–228PubMed
7.
Zurück zum Zitat Swerdlow SH, Campo E, Harris NL et al (2008) WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, 4th edn. IARC Press, Lyon Swerdlow SH, Campo E, Harris NL et al (2008) WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, 4th edn. IARC Press, Lyon
8.
Zurück zum Zitat Hans CP, Weisenburger DD, Greiner TC, Gascoyne RD, Delabie J, Ott G, Müller-Hermelink HK, Campo E, Braziel RM, Jaffe ES, Pan Z, Farinha P, Smith LM, Falini B, Banham AH, Rosenwald A, Staudt LM, Connors JM, Armitage JO, Chan WC (2004) Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 103:275–282CrossRefPubMed Hans CP, Weisenburger DD, Greiner TC, Gascoyne RD, Delabie J, Ott G, Müller-Hermelink HK, Campo E, Braziel RM, Jaffe ES, Pan Z, Farinha P, Smith LM, Falini B, Banham AH, Rosenwald A, Staudt LM, Connors JM, Armitage JO, Chan WC (2004) Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 103:275–282CrossRefPubMed
9.
Zurück zum Zitat Yan LX, Liu YH, Luo DL, Zhang F, Cheng Y, Luo XL, Xu J, Cheng J, Zhuang HG (2014) MYC expression in concert with BCL2 and BCL6 expression predicts outcome in Chinese patients with diffuse large B-cell lymphoma, not otherwise specified. PLoS One 9:e104068CrossRefPubMedPubMedCentral Yan LX, Liu YH, Luo DL, Zhang F, Cheng Y, Luo XL, Xu J, Cheng J, Zhuang HG (2014) MYC expression in concert with BCL2 and BCL6 expression predicts outcome in Chinese patients with diffuse large B-cell lymphoma, not otherwise specified. PLoS One 9:e104068CrossRefPubMedPubMedCentral
10.
Zurück zum Zitat Sun J, Lu Z, Yang D, Chen J (2011) Primary intestinal T-cell and NK-cell lymphomas: a clinicopathological and molecular study from China focused on type II enteropathy-associated T-cell lymphoma and primary intestinal NK-cell lymphoma. Mod Pathol 24:983–992CrossRefPubMed Sun J, Lu Z, Yang D, Chen J (2011) Primary intestinal T-cell and NK-cell lymphomas: a clinicopathological and molecular study from China focused on type II enteropathy-associated T-cell lymphoma and primary intestinal NK-cell lymphoma. Mod Pathol 24:983–992CrossRefPubMed
11.
Zurück zum Zitat Lomte N, Bandgar T, Khare S, Jadhav S, Lila A, Goroshi M, Kasaliwal R, Khadilkar K, Shah NS (2016) Bilateral adrenal masses: a single-centre experience. Endocr Connect 5:92–100CrossRefPubMedPubMedCentral Lomte N, Bandgar T, Khare S, Jadhav S, Lila A, Goroshi M, Kasaliwal R, Khadilkar K, Shah NS (2016) Bilateral adrenal masses: a single-centre experience. Endocr Connect 5:92–100CrossRefPubMedPubMedCentral
12.
Zurück zum Zitat Laurent C, Casasnovas O, Martin L, Chauchet A, Ghesquieres H, Aussedat G, Fornecker LM, Bologna S, Borot S, Laurent K, Bouillet B, Verges B, Petit JM (2017) Adrenal lymphoma: presentation, management and prognosis. QJM 110:103–109PubMed Laurent C, Casasnovas O, Martin L, Chauchet A, Ghesquieres H, Aussedat G, Fornecker LM, Bologna S, Borot S, Laurent K, Bouillet B, Verges B, Petit JM (2017) Adrenal lymphoma: presentation, management and prognosis. QJM 110:103–109PubMed
13.
Zurück zum Zitat Thompson MA, Habra MA, Routbort MJ, Holsinger FC, Perrier ND, Waguespack SG, Rodriguez MA (2007) Primary adrenal natural killer/T-cell nasal type lymphoma: first case report in adults. Am J Hematol 82:299–303CrossRefPubMed Thompson MA, Habra MA, Routbort MJ, Holsinger FC, Perrier ND, Waguespack SG, Rodriguez MA (2007) Primary adrenal natural killer/T-cell nasal type lymphoma: first case report in adults. Am J Hematol 82:299–303CrossRefPubMed
14.
Zurück zum Zitat Fujiwara T, Kawamura M, Sasaki A, Asahi H, Sasou S, Itoh S, Hiramori K (2001) Transient spontaneous regression of aggressive non-Hodgkin’s lymphoma confined to the adrenal glands. Ann Hematol 80:561–564CrossRefPubMed Fujiwara T, Kawamura M, Sasaki A, Asahi H, Sasou S, Itoh S, Hiramori K (2001) Transient spontaneous regression of aggressive non-Hodgkin’s lymphoma confined to the adrenal glands. Ann Hematol 80:561–564CrossRefPubMed
15.
Zurück zum Zitat Kim KM, Yoon DH, Lee SG, Lim SN, Sug LJ, Huh J, Suh C (2009) A case of primary adrenal diffuse large B-cell lymphoma achieving complete remission with rituximab-CHOP chemotherapy. J Korean Med Sci 24:525–528CrossRefPubMedPubMedCentral Kim KM, Yoon DH, Lee SG, Lim SN, Sug LJ, Huh J, Suh C (2009) A case of primary adrenal diffuse large B-cell lymphoma achieving complete remission with rituximab-CHOP chemotherapy. J Korean Med Sci 24:525–528CrossRefPubMedPubMedCentral
16.
Zurück zum Zitat De Miguel Sanchez C, Ruiz L, Gonzalez JL, Hernandez JL (2016) Acute adrenal insufficiency secondary to bilateral adrenal B-cell lymphoma: a case report and review of the literature. Ecancermedicalscience 10:634CrossRefPubMedPubMedCentral De Miguel Sanchez C, Ruiz L, Gonzalez JL, Hernandez JL (2016) Acute adrenal insufficiency secondary to bilateral adrenal B-cell lymphoma: a case report and review of the literature. Ecancermedicalscience 10:634CrossRefPubMedPubMedCentral
17.
Zurück zum Zitat Cedermark BJ, Sjoberg HE (1981) The clinical significance of metastases to the adrenal glands. Surg Gynecol Obstet 152:607–610PubMed Cedermark BJ, Sjoberg HE (1981) The clinical significance of metastases to the adrenal glands. Surg Gynecol Obstet 152:607–610PubMed
18.
Zurück zum Zitat Cedermark BJ, Sjoberg HE (1981) Adrenal activity in patients with advanced carcinomas. Surg Gynecol Obstet 152:461–465PubMed Cedermark BJ, Sjoberg HE (1981) Adrenal activity in patients with advanced carcinomas. Surg Gynecol Obstet 152:461–465PubMed
19.
Zurück zum Zitat Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, Rosenwald A, Boldrick JC, Sabet H, Tran T, Yu X, Powell JI, Yang L, Marti GE, Moore T, Hudson J, Lu L, Lewis DB, Tibshirani R, Sherlock G, Chan WC, Greiner TC, Weisenburger DD, Armitage JO, Warnke R, Levy R, Wilson W, Grever MR, Byrd JC, Botstein D, Brown PO, Staudt LM (2000) Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 403:503–511CrossRefPubMed Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, Rosenwald A, Boldrick JC, Sabet H, Tran T, Yu X, Powell JI, Yang L, Marti GE, Moore T, Hudson J, Lu L, Lewis DB, Tibshirani R, Sherlock G, Chan WC, Greiner TC, Weisenburger DD, Armitage JO, Warnke R, Levy R, Wilson W, Grever MR, Byrd JC, Botstein D, Brown PO, Staudt LM (2000) Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 403:503–511CrossRefPubMed
20.
Zurück zum Zitat Ide M, Fukushima N, Hisatomi T, Tsuneyoshi N, Tanaka M, Yokoo M, Tomimasu R, Funai N, Sueoka E (2007) Non-germinal cell phenotype and bcl-2 expression in primary adrenal diffuse large B-cell lymphoma. Leukemia & Lymphoma 48:2244–2246CrossRef Ide M, Fukushima N, Hisatomi T, Tsuneyoshi N, Tanaka M, Yokoo M, Tomimasu R, Funai N, Sueoka E (2007) Non-germinal cell phenotype and bcl-2 expression in primary adrenal diffuse large B-cell lymphoma. Leukemia & Lymphoma 48:2244–2246CrossRef
21.
Zurück zum Zitat Visco C, Li Y, Xu-Monette ZY, Miranda RN, Green TM, Li Y, Tzankov A, Wen W, Liu WM, Kahl BS, d'Amore ES, Montes-Moreno S, Dybkær K, Chiu A, Tam W, Orazi A, Zu Y, Bhagat G, Winter JN, Wang HY, O'Neill S, Dunphy CH, Hsi ED, Zhao XF, Go RS, Choi WW, Zhou F, Czader M, Tong J, Zhao X, van Krieken J, Huang Q, Ai W, Etzell J, Ponzoni M, Ferreri AJ, Piris MA, Møller MB, Bueso-Ramos CE, Medeiros LJ, Wu L, Young KH (2012) Comprehensive gene expression profiling and immunohistochemical studies support application of immunophenotypic algorithm for molecular subtype classification in diffuse large B-cell lymphoma: a report from the International DLBCL Rituximab-CHOP Consortium Program Study. Leukemia 26:2103–2113CrossRefPubMedPubMedCentral Visco C, Li Y, Xu-Monette ZY, Miranda RN, Green TM, Li Y, Tzankov A, Wen W, Liu WM, Kahl BS, d'Amore ES, Montes-Moreno S, Dybkær K, Chiu A, Tam W, Orazi A, Zu Y, Bhagat G, Winter JN, Wang HY, O'Neill S, Dunphy CH, Hsi ED, Zhao XF, Go RS, Choi WW, Zhou F, Czader M, Tong J, Zhao X, van Krieken J, Huang Q, Ai W, Etzell J, Ponzoni M, Ferreri AJ, Piris MA, Møller MB, Bueso-Ramos CE, Medeiros LJ, Wu L, Young KH (2012) Comprehensive gene expression profiling and immunohistochemical studies support application of immunophenotypic algorithm for molecular subtype classification in diffuse large B-cell lymphoma: a report from the International DLBCL Rituximab-CHOP Consortium Program Study. Leukemia 26:2103–2113CrossRefPubMedPubMedCentral
22.
Zurück zum Zitat Petrella T, Copie-Bergman C, Briere J et al (2017) BCL2 expression but not MYC and BCL2 coexpression predicts survival in elderly patients with diffuse large B-cell lymphoma independently of cell of origin in the phase 3 LNH03-6B trial. Ann Oncol 28:1042–1049CrossRefPubMed Petrella T, Copie-Bergman C, Briere J et al (2017) BCL2 expression but not MYC and BCL2 coexpression predicts survival in elderly patients with diffuse large B-cell lymphoma independently of cell of origin in the phase 3 LNH03-6B trial. Ann Oncol 28:1042–1049CrossRefPubMed
23.
Zurück zum Zitat Pfreundschuh M (2012) Growing importance of MYC/BCL2 immunohistochemistry in diffuse large B-cell lymphomas. J Clin Oncol 30:3433–3435CrossRefPubMed Pfreundschuh M (2012) Growing importance of MYC/BCL2 immunohistochemistry in diffuse large B-cell lymphomas. J Clin Oncol 30:3433–3435CrossRefPubMed
24.
Zurück zum Zitat Staiger AM, Ziepert M, Horn H, Scott DW, Barth TFE, Bernd HW, Feller AC, Klapper W, Szczepanowski M, Hummel M, Stein H, Lenze D, Hansmann ML, Hartmann S, Möller P, Cogliatti S, Lenz G, Trümper L, Löffler M, Schmitz N, Pfreundschuh M, Rosenwald A, Ott G, for the German High-Grade Lymphoma Study Group (2017) Clinical impact of the cell-of-origin classification and the MYC/ BCL2 dual expresser status in diffuse large B-cell lymphoma treated within prospective clinical trials of the German high-grade non-Hodgkin’s lymphoma study group. J Clin Oncol 35:2515–2526CrossRefPubMed Staiger AM, Ziepert M, Horn H, Scott DW, Barth TFE, Bernd HW, Feller AC, Klapper W, Szczepanowski M, Hummel M, Stein H, Lenze D, Hansmann ML, Hartmann S, Möller P, Cogliatti S, Lenz G, Trümper L, Löffler M, Schmitz N, Pfreundschuh M, Rosenwald A, Ott G, for the German High-Grade Lymphoma Study Group (2017) Clinical impact of the cell-of-origin classification and the MYC/ BCL2 dual expresser status in diffuse large B-cell lymphoma treated within prospective clinical trials of the German high-grade non-Hodgkin’s lymphoma study group. J Clin Oncol 35:2515–2526CrossRefPubMed
25.
Zurück zum Zitat Kawamoto K, Miyoshi H, Yoshida N, Nakamura N, Ohshima K, Sone H, Takizawa J (2016) MYC translocation and/or BCL 2 protein expression are associated with poor prognosis in diffuse large B-cell lymphoma. Cancer Sci 107:853–861CrossRefPubMedPubMedCentral Kawamoto K, Miyoshi H, Yoshida N, Nakamura N, Ohshima K, Sone H, Takizawa J (2016) MYC translocation and/or BCL 2 protein expression are associated with poor prognosis in diffuse large B-cell lymphoma. Cancer Sci 107:853–861CrossRefPubMedPubMedCentral
26.
Zurück zum Zitat Rashidi A, Bergeron CW, Fisher SI, Chen IA (2013) Primary adrenal de novo CD5-positive diffuse large B cell lymphoma. Ann Hematol 92:1281–1282CrossRefPubMed Rashidi A, Bergeron CW, Fisher SI, Chen IA (2013) Primary adrenal de novo CD5-positive diffuse large B cell lymphoma. Ann Hematol 92:1281–1282CrossRefPubMed
27.
Zurück zum Zitat Ichikawa S, Fukuhara N, Inoue A, Katsushima H, Ohba R, Katsuoka Y, Onishi Y, Yamamoto J, Sasaki O, Nomura J, Fukuhara O, Ishizawa K, Ichinohasama R, Harigae H (2013) Clinicopathological analysis of primary adrenal diffuse large B-cell lymphoma: effectiveness of rituximab-containing chemotherapy including central nervous system prophylaxis. Exp Hematol Oncol 2:19CrossRefPubMedPubMedCentral Ichikawa S, Fukuhara N, Inoue A, Katsushima H, Ohba R, Katsuoka Y, Onishi Y, Yamamoto J, Sasaki O, Nomura J, Fukuhara O, Ishizawa K, Ichinohasama R, Harigae H (2013) Clinicopathological analysis of primary adrenal diffuse large B-cell lymphoma: effectiveness of rituximab-containing chemotherapy including central nervous system prophylaxis. Exp Hematol Oncol 2:19CrossRefPubMedPubMedCentral
28.
Zurück zum Zitat Niitsu N, Okamoto M, Tamaru JI, Yoshino T, Nakamura N, Nakamura S, Ohshima K, Nakamine H, Hirano M (2010) Clinicopathologic characteristics and treatment outcome of the addition of rituximab to chemotherapy for CD5-positive in comparison with CD5-negative diffuse large B-cell lymphoma. Ann Oncol 21:2069–2074CrossRefPubMed Niitsu N, Okamoto M, Tamaru JI, Yoshino T, Nakamura N, Nakamura S, Ohshima K, Nakamine H, Hirano M (2010) Clinicopathologic characteristics and treatment outcome of the addition of rituximab to chemotherapy for CD5-positive in comparison with CD5-negative diffuse large B-cell lymphoma. Ann Oncol 21:2069–2074CrossRefPubMed
29.
Zurück zum Zitat Taniguchi M, Oka K, Hiasa A, Yamaguchi M, Ohno T, Kita K, Shiku H (1998) De novo CD5+ diffuse large B-cell lymphomas express VH genes with somatic mutation. Blood 91:1145–1151PubMed Taniguchi M, Oka K, Hiasa A, Yamaguchi M, Ohno T, Kita K, Shiku H (1998) De novo CD5+ diffuse large B-cell lymphomas express VH genes with somatic mutation. Blood 91:1145–1151PubMed
30.
Zurück zum Zitat Yamaguchi M, Seto M, Okamoto M, Ichinohasama R, Nakamura N, Yoshino T, Suzumiya J, Murase T, Miura I, Akasaka T, Tamaru J, Suzuki R, Kagami Y, Hirano M, Morishima Y, Ueda R, Shiku H, Nakamura S (2002) De novo CD5+ diffuse large B-cell lymphoma: a clinicopathologic study of 109 patients. Blood 99:815–821CrossRefPubMed Yamaguchi M, Seto M, Okamoto M, Ichinohasama R, Nakamura N, Yoshino T, Suzumiya J, Murase T, Miura I, Akasaka T, Tamaru J, Suzuki R, Kagami Y, Hirano M, Morishima Y, Ueda R, Shiku H, Nakamura S (2002) De novo CD5+ diffuse large B-cell lymphoma: a clinicopathologic study of 109 patients. Blood 99:815–821CrossRefPubMed
31.
Zurück zum Zitat Yamaguchi M, Nakamura N, Suzuki R, Kagami Y, Okamoto M, Ichinohasama R, Yoshino T, Suzumiya J, Murase T, Miura I, Ohshima K, Nishikori M, Tamaru JI, Taniwaki M, Hirano M, Morishima Y, Ueda R, Shiku H, Nakamura S (2008) De novo CD5+ diffuse large B-cell lymphoma: results of a detailed clinicopathological review in 120 patients. Haematologica 93:1195–1202CrossRefPubMed Yamaguchi M, Nakamura N, Suzuki R, Kagami Y, Okamoto M, Ichinohasama R, Yoshino T, Suzumiya J, Murase T, Miura I, Ohshima K, Nishikori M, Tamaru JI, Taniwaki M, Hirano M, Morishima Y, Ueda R, Shiku H, Nakamura S (2008) De novo CD5+ diffuse large B-cell lymphoma: results of a detailed clinicopathological review in 120 patients. Haematologica 93:1195–1202CrossRefPubMed
32.
Zurück zum Zitat Ohkura Y, Shindoh J, Haruta S, Kaji D, Ota Y, Fujii T, Hashimoto M, Watanabe G, Matsuda M (2015) Primary adrenal lymphoma possibly associated with Epstein-Barr virus reactivation due to immunosuppression under methotrexate therapy. Medicine 94:e1270CrossRefPubMedPubMedCentral Ohkura Y, Shindoh J, Haruta S, Kaji D, Ota Y, Fujii T, Hashimoto M, Watanabe G, Matsuda M (2015) Primary adrenal lymphoma possibly associated with Epstein-Barr virus reactivation due to immunosuppression under methotrexate therapy. Medicine 94:e1270CrossRefPubMedPubMedCentral
33.
Zurück zum Zitat Moonim MT, Nasir A, Hubbard J, Ketley N, Fields P (2017) Synchronous microscopic Epstein-Barr virus-positive diffuse large B-cell lymphoma of the adrenal and lymphoplasmacytic lymphoma: De novo disease or transformation? Int J Surg Pathol 25:326–332CrossRefPubMed Moonim MT, Nasir A, Hubbard J, Ketley N, Fields P (2017) Synchronous microscopic Epstein-Barr virus-positive diffuse large B-cell lymphoma of the adrenal and lymphoplasmacytic lymphoma: De novo disease or transformation? Int J Surg Pathol 25:326–332CrossRefPubMed
34.
Zurück zum Zitat Ohsawa M, Tomita Y, Hashimoto M, Yasunaga Y, Kanno H, Aozasa K (1996) Malignant lymphoma of the adrenal gland: its possible correlation with the Epstein-Barr virus. Mod Pathol 9:534–543PubMed Ohsawa M, Tomita Y, Hashimoto M, Yasunaga Y, Kanno H, Aozasa K (1996) Malignant lymphoma of the adrenal gland: its possible correlation with the Epstein-Barr virus. Mod Pathol 9:534–543PubMed
35.
Zurück zum Zitat Lu TX, Liang JH, Miao Y, Fan L, Wang L, Qu XY, Cao L, Gong QX, Wang Z, Zhang ZH, Xu W, Li JY (2015) Epstein-Barr virus positive diffuse large B-cell lymphoma predict poor outcome, regardless of the age. Sci Rep 5:12168CrossRefPubMedPubMedCentral Lu TX, Liang JH, Miao Y, Fan L, Wang L, Qu XY, Cao L, Gong QX, Wang Z, Zhang ZH, Xu W, Li JY (2015) Epstein-Barr virus positive diffuse large B-cell lymphoma predict poor outcome, regardless of the age. Sci Rep 5:12168CrossRefPubMedPubMedCentral
36.
Zurück zum Zitat Li W, Lin W, Ma C, Zhang L, Sun H (2016) A case of intravascular large B-cell lymphoma in the left adrenal and another tumor in the right adrenal detected by (18)F-FDG PET/CT. Hellenic Journal of Nuclear Medicine 19:57–59PubMed Li W, Lin W, Ma C, Zhang L, Sun H (2016) A case of intravascular large B-cell lymphoma in the left adrenal and another tumor in the right adrenal detected by (18)F-FDG PET/CT. Hellenic Journal of Nuclear Medicine 19:57–59PubMed
37.
Zurück zum Zitat Srivatsa S, Sharma J, Logani S (2008) Intravascular lymphoma: an unusual diagnostic outcome of an incidentally detected adrenal mass. Endocr Pract 14:884–8884CrossRefPubMed Srivatsa S, Sharma J, Logani S (2008) Intravascular lymphoma: an unusual diagnostic outcome of an incidentally detected adrenal mass. Endocr Pract 14:884–8884CrossRefPubMed
38.
Zurück zum Zitat Takahashi Y, Iida K, Hino Y, Ohara T, Kurahashi T, Tashiro T, Chihara K (2012) Silent intravascular lymphoma initially manifesting as a unilateral adrenal incidentaloma. Case Rep Med 2012:849285CrossRefPubMedPubMedCentral Takahashi Y, Iida K, Hino Y, Ohara T, Kurahashi T, Tashiro T, Chihara K (2012) Silent intravascular lymphoma initially manifesting as a unilateral adrenal incidentaloma. Case Rep Med 2012:849285CrossRefPubMedPubMedCentral
39.
Zurück zum Zitat Singh D, Kumar L, Sharma A, Vijayaraghavan M, Thulkar S, Tandon N (2004) Adrenal involvement in non-Hodgkin’s lymphoma: four cases and review of literature. Leukemia & Lymphoma 45:789–794CrossRef Singh D, Kumar L, Sharma A, Vijayaraghavan M, Thulkar S, Tandon N (2004) Adrenal involvement in non-Hodgkin’s lymphoma: four cases and review of literature. Leukemia & Lymphoma 45:789–794CrossRef
Metadaten
Titel
Primary adrenal diffuse large B cell lymphoma: a clinicopathological and molecular study from China
verfasst von
Jing Zhang
Jian Sun
Jun Feng
Yufeng Luo
Qing Ling
Shafei Wu
Xuan Zeng
Zhiyong Liang
Publikationsdatum
25.05.2018
Verlag
Springer Berlin Heidelberg
Erschienen in
Virchows Archiv / Ausgabe 1/2018
Print ISSN: 0945-6317
Elektronische ISSN: 1432-2307
DOI
https://doi.org/10.1007/s00428-018-2378-1

Weitere Artikel der Ausgabe 1/2018

Virchows Archiv 1/2018 Zur Ausgabe

Neu im Fachgebiet Pathologie

Molekularpathologische Untersuchungen im Wandel der Zeit

Open Access Biomarker Leitthema

Um auch an kleinen Gewebeproben zuverlässige und reproduzierbare Ergebnisse zu gewährleisten ist eine strenge Qualitätskontrolle in jedem Schritt des Arbeitsablaufs erforderlich. Eine nicht ordnungsgemäße Prüfung oder Behandlung des …

Vergleichende Pathologie in der onkologischen Forschung

Pathologie Leitthema

Die vergleichende experimentelle Pathologie („comparative experimental pathology“) ist ein Fachbereich an der Schnittstelle von Human- und Veterinärmedizin. Sie widmet sich der vergleichenden Erforschung von Gemeinsamkeiten und Unterschieden von …

Gastrointestinale Stromatumoren

Open Access GIST CME-Artikel

Gastrointestinale Stromatumoren (GIST) stellen seit über 20 Jahren ein Paradigma für die zielgerichtete Therapie mit Tyrosinkinaseinhibitoren dar. Eine elementare Voraussetzung für eine mögliche neoadjuvante oder adjuvante Behandlung bei …

Personalisierte Medizin in der Onkologie

Aufgrund des erheblichen technologischen Fortschritts in der molekularen und genetischen Diagnostik sowie zunehmender Erkenntnisse über die molekulare Pathogenese von Krankheiten hat in den letzten zwei Jahrzehnten ein grundlegender …